ArticleFrontiers in pharmacology2025
Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China.
Weiwei Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.